Anne-Marie Russell1,2, Huzaifa Adamali3, Philip L Molyneaux1,2, Pauline T Lukey4, Richard P Marshall4, Elisabetta A Renzoni1,2, Athol U Wells1,2, Toby M Maher1,2. 1. 1 National Institute for Health Research Biomedical Research Unit, Royal Brompton Hospital, London, United Kingdom. 2. 2 Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, London, United Kingdom. 3. 3 Bristol Interstitial Lung Disease Service, North Bristol Lung Centre, Southmead Hospital, Westbury-on-Trym, United Kingdom; and. 4. 4 Fibrosis and Lung Injury DPU, GlaxoSmithKline R&D, Stevenage, Herts, United Kingdom.
Abstract
RATIONALE: Recent clinical trial successes have created an urgent need for earlier and more sensitive endpoints of disease progression in idiopathic pulmonary fibrosis (IPF). Domiciliary spirometry permits more frequent measurement of FVC than does hospital-based assessment, which therefore affords the opportunity for a more granular insight into changes in IPF progression. OBJECTIVES: To determine the feasibility and reliability of measuring daily FVC in individuals with IPF. METHODS: Subjects with IPF were given handheld spirometers and instruction on how to self-administer spirometry. Subjects recorded daily FEV1 and FVC for up to 490 days. Clinical assessment and hospital-based spirometry was undertaken at 6 and 12 months, and outcome data were collected for 3 years. MEASUREMENTS AND MAIN RESULTS: Daily spirometry was recorded by 50 subjects for a median period of 279 days (range, 13-490 d). There were 18 deaths during the active study period. Home spirometry showed excellent correlation with hospital-obtained readings. The rate of decline in FVC was highly predictive of outcome and subsequent mortality when measured at 3 months (hazard ratio [HR], 1.040; 95% confidence interval [CI], 1.021-1.062; P ≤ 0.001), 6 months (HR, 1.024; 95% CI, 1.014-1.033; P < 0.001), and 12 months (HR, 1.012; 95% CI, 1.007-1.016; P = 0.001). CONCLUSIONS: Measurement of daily home spirometry in patients with IPF is highly clinically informative and is feasible to perform for most of these patients. The relationship between mortality and rate of change of FVC at 3 months suggests that daily FVC may be of value as a primary endpoint in short proof-of-concept IPF studies.
RATIONALE: Recent clinical trial successes have created an urgent need for earlier and more sensitive endpoints of disease progression in idiopathic pulmonary fibrosis (IPF). Domiciliary spirometry permits more frequent measurement of FVC than does hospital-based assessment, which therefore affords the opportunity for a more granular insight into changes in IPF progression. OBJECTIVES: To determine the feasibility and reliability of measuring daily FVC in individuals with IPF. METHODS: Subjects with IPF were given handheld spirometers and instruction on how to self-administer spirometry. Subjects recorded daily FEV1 and FVC for up to 490 days. Clinical assessment and hospital-based spirometry was undertaken at 6 and 12 months, and outcome data were collected for 3 years. MEASUREMENTS AND MAIN RESULTS: Daily spirometry was recorded by 50 subjects for a median period of 279 days (range, 13-490 d). There were 18 deaths during the active study period. Home spirometry showed excellent correlation with hospital-obtained readings. The rate of decline in FVC was highly predictive of outcome and subsequent mortality when measured at 3 months (hazard ratio [HR], 1.040; 95% confidence interval [CI], 1.021-1.062; P ≤ 0.001), 6 months (HR, 1.024; 95% CI, 1.014-1.033; P < 0.001), and 12 months (HR, 1.012; 95% CI, 1.007-1.016; P = 0.001). CONCLUSIONS: Measurement of daily home spirometry in patients with IPF is highly clinically informative and is feasible to perform for most of these patients. The relationship between mortality and rate of change of FVC at 3 months suggests that daily FVC may be of value as a primary endpoint in short proof-of-concept IPF studies.
Entities:
Keywords:
biomarker; clinical trials; interstitial lung disease; personalized medicine
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Talmadge E King; Lisa Lancaster; Paul W Noble; Steven A Sahn; Michiel Thomeer; Dominique Valeyre; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2011-09-22 Impact factor: 21.405
Authors: Roland M du Bois; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Jonathan A Leff; Paul W Noble; Steven A Sahn; Dominique Valeyre; Derek Weycker; Talmadge E King Journal: Eur Respir J Date: 2013-12-05 Impact factor: 16.671
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King Journal: Am J Respir Crit Care Med Date: 2011-08-15 Impact factor: 21.405
Authors: Luca Richeldi; Christopher J Ryerson; Joyce S Lee; Paul J Wolters; Laura L Koth; Brett Ley; Brett M Elicker; Kirk D Jones; Talmadge E King; Jay H Ryu; Harold R Collard Journal: Thorax Date: 2012-03-17 Impact factor: 9.139
Authors: Elizabeth A Belloli; Xin Wang; Susan Murray; Ginia Forrester; Adrian Weyhing; Jules Lin; Tammy Ojo; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Phillip L Molyneaux; Michael J Cox; Saffron A G Willis-Owen; Patrick Mallia; Kirsty E Russell; Anne-Marie Russell; Elissa Murphy; Sebastian L Johnston; David A Schwartz; Athol U Wells; William O C Cookson; Toby M Maher; Miriam F Moffatt Journal: Am J Respir Crit Care Med Date: 2014-10-15 Impact factor: 30.528
Authors: Ashley R Rackow; David J Nagel; Claire McCarthy; Jennifer Judge; Shannon Lacy; Margaret A T Freeberg; Thomas H Thatcher; R Matthew Kottmann; Patricia J Sime Journal: Eur Respir J Date: 2020-11-26 Impact factor: 16.671
Authors: Kerri A Johannson; Eric Vittinghoff; Julie Morisset; Paul J Wolters; Elizabeth M Noth; John R Balmes; Harold R Collard Journal: Chest Date: 2018-02-07 Impact factor: 9.410
Authors: Kerri A Johannson; Eric Vittinghoff; Julie Morisset; Joyce S Lee; John R Balmes; Harold R Collard Journal: Eur Respir J Date: 2017-07-05 Impact factor: 16.671
Authors: Imre Noth; Vincent Cottin; Nazia Chaudhuri; Tamera J Corte; Kerri A Johannson; Marlies Wijsenbeek; Stephane Jouneau; Andreas Michael; Manuel Quaresma; Klaus B Rohr; Anne-Marie Russell; Susanne Stowasser; Toby M Maher Journal: Eur Respir J Date: 2021-07-08 Impact factor: 16.671
Authors: Jane Turner; Qianchuan He; Kelsey Baker; Lisa Chung; Adrian Lazarevic-Fogelquist; Danika Bethune; Jesse Hubbard; Margaret Guerriero; Ajay Sheshadri; Karen L Syrjala; Paul J Martin; Michael Boeckh; Stephanie J Lee; Ted Gooley; Mary E Flowers; Guang-Shing Cheng Journal: Transplant Cell Ther Date: 2021-03-26
Authors: Catharina C Moor; Sander I van Leuven; Marlies S Wijsenbeek; Madelon C Vonk Journal: Rheumatology (Oxford) Date: 2021-05-14 Impact factor: 7.580